GSK opens UK respiratory manufacturing facility

pharmafield logo - pharma news

GSK has opened a £56 million manufacturing facility in Ware, creating 150 new UK jobs.

The company created the state of the art facility in response to growing export demand for GSK’s portfolio of respiratory medicines delivered by the Ellipta inhaler.

The new 4500m2 facility was opened by UK Life Sciences Minister George Freeman MP and GSK Chief Executive Officer Sir Andrew Witty. It is the latest expansion for Ellipta manufacturing at Ware, with investment totalling over £100 million over the past five years. More than 400 jobs have been created at the site since 2013, including over 30 apprentice and 50 graduate roles, forming the total workforce of 1200.

The new facility is expected to almost double production of Ellipta inhalers at Ware to at least 37 million per year by 2017. 95% of these will be exported.  

GSK’s CEO Sir Andrew Witty said: “We have been leaders in respiratory since the 1960s when we first began making inhalers for the treatment of respiratory diseases in Ware and it continues to be a critically important site for us, both in terms of researching and developing innovative new inhaler technology, and as a world-leading manufacturing hub. The new facility will increase capacity to meet growing demand for our new portfolio of respiratory medicines worldwide.”

George Freeman MP said: “As well as driving growth and creating 150 new jobs, this expansion of GSK’s medicines manufacturing facility in Ware is a strong endorsement of the UK’s leadership in manufacturing and respiratory medicine.”